Binding of salicylate to albumin  by McArthur, J.N. & Smith, M.J.H.
X . Production 
In man, a variable amount of circulating sakykite 
is bound to semm albumin 61 Y 23. The free, i.e. un- 
bound, salicylate is, preslunatiy, ihe fraction which 
enters body cells and subsequently determines the 
tissue levels and hence causes the pharmacological 
clinical and toxjc actions of 2he drug. Conventional 
laboratory procedures measure the total salicylate 
concentration in the serum and give no indication of 
the ratio between bound and unbound drug. This 
ratio may be of significance in cases 0;; acute poison- 
ing, since therz is some evidence Zha? a smaller pro- 
portion of salicylate is bound at high than at low 
salic~late concentrations [33. In addiiion, &here are 
differences in the extent to which salicyiate is bound 
to the plasma proteins of different species 143 _ This 
situarion may also apply to individuals within species 
because albumin molecules in some patients appear 
to have fewer binding sites than in others IS]. Thus, 
subjects who show a low capacity to bind salicylates 
to Iheir plasma albumin may b,e a? higher risk of in- 
toxication after the ingestion of a single, !arge dose 
of the drug because of the greater proportion of free 
sahcylate able to enter the cells from the circulation. 
A convenient and reliable method for the separation 
and determination of protein-hound salicylate and 
free, i.e. unbound, salicylate would therefore provide 
much useful information. Porter and Guy 163 d&sed 
a rapid gel filtration technique to separate ihe above 
fractions, the final estimation utilising a sensitive 
fluorophotometdc Bay. The separative procedure 
uses the cross-linked Dextran gel (Sephadex) contin- 
ed in a CO~NOII of fixed dimensimis. Subsequent du- 
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tion with pho,@ate buffer apparently erM&d the 
unbound ftiction to be completely separated f&m 
the bound fraction. We have found that -varying the 
length of the gel column alters the proportion of 
sahcylate lmmd to purified bovine albumin. 
2. Materials and methods 
Crysme bovine serum albumin (Sigma Chem- 
ical Co_) G-25 Med.km Grade Sephadex (Pharmacia) 
and sodium salicylate @i&h PharmacopoeiaI grade) 
were used. Tfie buffer employed was 0.1 M phosphate. 
pH 7-4, d&on&d water b&g used throughout_ 1 ml 
aliquots of a 5% (w/v] soMon of the bovine albu- 
min in the phosphate buffer were exposed to salicylate 
concen&ations zmg;lg from 5 to 200 mg per 300 mf 
at 37°C for one hour before gel fltratbn. TIte pro- 
cedure described by Putter and Guy I63 was followed, 
except that ihe length of gel co1mnn was varied over 
the range EC-240 mm and in the final assay an activ- 
ating wavelength of 294 ~IIJ_I and a derectig wavelength 
of 4 13 ~il~i were used. 
3. Results 
Fig. 1 illustrates the separation of free salicylate 
from the proteinhound f%&on, using a 100 mm 
column and a bovine albumin solution exposed to a 
salicylate oncentration of 20 mg vr 3 00 ml. 
The effecti of var$ng tie leng& of ihe gel co- 
Iumn on the proportion of protein-bound ticylate 
in bovine albumin solutions exposed to sal%@ate 
concen’iratioris ran&g front S-200 mg per 1430 rdl 
are shown in fig. 2. The results of fjg- 2 show that the 
apparent percenhge of protein&ound ticylate at 
any one sakyk~te concentration varies with the length 
of txdumn; thus when the bovine albumin was exposed 
to a salicylate concentration of 20 mg per 100 ml, sub- 
sequent passage ?hron& an Xl mm column gave a 
X&E of48% for the protein-bmmd sakylaxe, whereas 
~3.5 a 240 mm column the corresponding value was 
id%. Th ordinaie axis (fig. 2) represents a ‘&eoreticd 
zerdength c13lmn.i1. The curves for the hQ+er sak7ylzt.e 
concea?mtions (SO and 200 ag per 100 m!) intersect 
this axis zf values corre!~onding to 60 and 20% of pro- 
tein-hmd salkylate, but &is does net OZCM with the 
cures for the lower sakylate concentrations (S and 
20 mg per 100 mt). 
4. Ixscnr;ion 
Fig. 2. Variation in ‘&e prqxuation or proleiu-bound sky- 
late with length of gel filtration column. TX bovkie albumin 
~~lutkns were exposed for one hr at 37OC to the follorv~g 
salicylatcconcentraticns: 3 5 mg per IOD .A_ * 20 mg per 
100 ml, q 50 mg per 130 ml, and 0 700 mg per lC!Ir ml_ 
tent of protebbinding of saky!ate. The method of 
Potter and Guy cannot therefore be Lsed to obtain 
an estimrte of the degree of protein t inding of SE&- 
cylate to either puri%ed aYfhn~in of scrur~ 
The extent of proteirr-bhhg w&zh needs to be 
measured is that existing in either the protein solu- 
tion or the sen?m before ap&ication to the gel CG- 
hmm. when the present data are plctied, as in fig. 2, 
it js possible to ext-rpolate the curves t3 2 ihecjreticd 
zero-ien@ column and +&e values ob--ained with tKs 
column should be cquhlent to those oscutig in 
the soludion befme gel f&ration. WiS sdkylate con- 
centratiom bdow 20 mg per 1013 IT& :.e. i? the range 
ocwn%ng in III.IIKEI serum durhg therapy, -tiwGly 
ZIU the sakylate is Sound to the protek. On the other 
hand, at salicylate concen?ra&ns of 50 mg per 100 
nil and above, i.e. in the range associated with the 
development of acute toxic sympton~, az~ increeg 
gmpodion ofsalicy~ate is&the he h-action. An 
inteqlxMk3n 0f this finding 53 *Ihat ae development 
of toxic spph3ti, suck 3s hy@emnt3&. tiy be 
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